MYRIAD GENETICS (MYGN) Q3 2025 TL;DR: Significant financial deterioration driven by massive asset write-downs, partially offset by strategic debt refinancing.
FINANCIAL PERFORMANCE (9 MONTHS ENDED SEPT 30, 2025): Revenue declined to \(614.7M (\)627.0M in 2024). Net Loss widened substantially to \((358.0) Million, or \)(3.88) per diluted share (vs. \((84.8)M loss in 2024). Q3 performance showed a loss of \)(27.4)M.
MATERIAL EVENTS AND BALANCE SHEET: The quarter was defined by a $316.7 Million impairment charge (\(234.7M Goodwill, \)82.0M Intangibles), causing Total Assets to fall to $728.1M (from
...